(RxWiki News) The US Food and Drug Administration has approved a new treatment option for type 2 diabetes.
That new option is Sanofi's Adlyxin (lixisenatide), which comes in a disposable, prefilled injectable pen.
Adlyxin belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists and treats type 2 diabetes by improving glucose (sugar) control. It is to be used in conjunction with diet and exercise.
This medication is administered once a day under the skin (subcutaneous) in the stomach area, thigh or upper arm.
Adlyxin is not insulin and not to be used in the place of long-acting insulin.
This medication's approval was based on the results of 10 clinical trials in which Adlyxin appeared to improve hemoglobin A1c levels — a measure of blood glucose (sugar) levels.
Common side effects included nausea, vomiting, diarrhea and headache. This medication may also cause dizziness. Do not drive or operate heavy machinery until you know how this medication affects you.
This medication is not to be used in those with type 1 diabetes or those with diabetic ketoacidosis (an increase in ketones in the blood or urine).